Computational Identification of Antigen-Binding Antibody Fragments

Determining which parts of the Ab are essential for Ag recognition and binding is crucial for understanding B cell–mediated immunity. Identification of fragments of Abs that maintain specificity to the Ag will also allow for the development of improved Ab-based therapy and diagnostics. In this article, we show that structural analysis of Ab–Ag complexes reveals which fragments of the Ab may bind the Ag on their own. In particular, it is possible to predict whether a given CDR is likely to bind the Ag as a peptide by analyzing the energetic contribution of each CDR to Ag binding and by assessing to what extent the interaction between that CDR and the Ag depends on other CDRs. To demonstrate this, we analyzed five Ab–Ag complexes and predicted for each of them which of the CDRs may bind the Ag on its own as a peptide. We then show that these predictions are in agreement with our experimental analysis and with previously published experimental results. These findings promote our understanding of the modular nature of Ab–Ag interactions and lay the foundation for the rational design of active CDR-derived peptides.

[1]  R. Porter The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. , 1959, The Biochemical journal.

[2]  F. Karush,et al.  THE SUBUNITS OF PURIFIED RABBIT ANTIBODY. , 1964, Biochemistry.

[3]  D. Pressman,et al.  Specific Binding Activity of Isolated Light Chains of Antibodies , 1967, Science.

[4]  C. Selve,et al.  Reactifs de couplage peptidique I (1) - l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.) , 1975 .

[5]  Noncovalent association of heavy and light chains of human immunoglobulins. IV. The roles of the CH1 and CL domains in idiotypic expression. , 1985, Journal of immunology.

[6]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[7]  J. Blalock,et al.  Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. , 1988, Science.

[8]  J. Wells,et al.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.

[9]  P. T. Jones,et al.  Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.

[10]  Development of biologically active peptides based on antibody structure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[12]  E. Giralt,et al.  Cyclization of disulfide-containing peptides in solid-phase synthesis. , 2009, International journal of peptide and protein research.

[13]  B. Persson,et al.  Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins , 1991 .

[14]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[15]  M Kahn,et al.  Design and synthesis of a mimetic from an antibody complementarity-determining region. , 1991, Science.

[16]  D. Weiner,et al.  Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. , 1991, The Journal of biological chemistry.

[17]  M. Berry,et al.  Use of antibody fragments in immunoaffinity chromatography. Comparison of FV fragments, VH fragments and paralog peptides. , 1992, Journal of chromatography.

[18]  V. Garsky,et al.  Peptide sequences from the hypervariable regions of two monoclonal anti-idiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells. , 1992, The Journal of biological chemistry.

[19]  B. Wahrén,et al.  A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Lasonder,et al.  Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance. , 1994, Journal of chromatography. A.

[21]  K. Tsumoto,et al.  Effect of the order of antibody variable regions on the expression of the single-chain HyHEL10 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. , 1994, Biochemical and biophysical research communications.

[22]  Molecular aspects of antibody-antigen interactions: size reduction of a herpes simplex virus neutralizing antibody and its antigen , 1996 .

[23]  V. Ose,et al.  Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity. , 1996, Human antibodies and hybridomas.

[24]  D. Myszka,et al.  Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. , 1997, Current opinion in biotechnology.

[25]  D. Laune,et al.  Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins* , 1997, The Journal of Biological Chemistry.

[26]  J. Scardina,et al.  Peptides Derived from the Complementarity-determining Regions of Anti-Mac-1 Antibodies Block Intercellular Adhesion Molecule-1 Interaction with Mac-1* , 1998, The Journal of Biological Chemistry.

[27]  S. Shapiro,et al.  Cardiolipin binding a light chain from lupus-prone mice. , 1998, Biochemistry.

[28]  D. Phillips,et al.  Structure‐based design of peptides that recognize the CD4 binding domain of HIV‐1 gp120 , 1998, AIDS.

[29]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[30]  P. Pothier,et al.  Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice , 1998, Journal of Virology.

[31]  G. Johnson,et al.  Preferred CDRH3 lengths for antibodies with defined specificities. , 1998, International immunology.

[32]  K. Tsumoto,et al.  Crystal Structure of Anti-Hen Egg White Lysozyme Antibody (HyHEL-10) Fv-Antigen Complex , 1999, The Journal of Biological Chemistry.

[33]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[34]  Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. , 2000, Biochemistry. Biokhimiia.

[35]  Donald M. O'Rourke,et al.  Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo , 2000, Nature Biotechnology.

[36]  A. Berezov,et al.  Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. , 2001, Journal of medicinal chemistry.

[37]  K. Tsumoto,et al.  Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity‐determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target , 2002, FEBS letters.

[38]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[39]  P. Hudson,et al.  Engineered antibodies , 2003, Nature Medicine.

[40]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[41]  J. C. Almagro,et al.  Identification of differences in the specificity‐determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires , 2004, Journal of molecular recognition : JMR.

[42]  F. Dammacco,et al.  Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. , 2004, Immunology letters.

[43]  Yan Li,et al.  Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. , 2005, Immunology letters.

[44]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[45]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[46]  B. Cai,et al.  Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting , 2007, Nature Biotechnology.

[47]  S. Batra,et al.  Engineering antibodies for clinical applications. , 2007, Trends in biotechnology.

[48]  K. Tsumoto,et al.  Structural Consequences of Mutations in Interfacial Tyr Residues of a Protein Antigen-Antibody Complex , 2007, Journal of Biological Chemistry.

[49]  Haruki Nakamura,et al.  Structural classification of CDR‐H3 revisited: A lesson in antibody modeling , 2008, Proteins.

[50]  M. Juliano,et al.  Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities , 2008, PloS one.

[51]  T. Knöchel,et al.  Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. , 2008, Cancer cell.

[52]  Ruth Nussinov,et al.  Computational Protein-Protein Interactions , 2009 .

[53]  J. Desmet,et al.  A Combinatorial Approach for the Design of Complementarity-determining Region-derived Peptidomimetics with in Vitro Anti-tumoral Activity* , 2009, The Journal of Biological Chemistry.

[54]  Janice M Reichert,et al.  Development trends for therapeutic antibody fragments , 2009, Nature Biotechnology.

[55]  Yanay Ofran Prediction of Protein Interaction Sites , 2009 .

[56]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[57]  S. Dübel,et al.  Antibody Engineering , 2010, Springer Berlin Heidelberg.

[58]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[59]  Holger Gohlke,et al.  DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein–protein interactions , 2010, Nucleic Acids Res..

[60]  D. Ponde,et al.  Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. , 2011, Bioorganic & medicinal chemistry letters.

[61]  Lora Hamuro,et al.  A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S] , 2011, Journal of Lipid Research.

[62]  Jinyan Li,et al.  Antibody-Specified B-Cell Epitope Prediction in Line with the Principle of Context-Awareness , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[63]  E. Baba,et al.  [Development trends for therapeutic antibody]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.